CO6210755A2 - Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicos - Google Patents
Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicosInfo
- Publication number
- CO6210755A2 CO6210755A2 CO09074363A CO09074363A CO6210755A2 CO 6210755 A2 CO6210755 A2 CO 6210755A2 CO 09074363 A CO09074363 A CO 09074363A CO 09074363 A CO09074363 A CO 09074363A CO 6210755 A2 CO6210755 A2 CO 6210755A2
- Authority
- CO
- Colombia
- Prior art keywords
- antibody
- binds
- polypeptide
- app
- antagonists
- Prior art date
Links
- 239000005557 antagonist Substances 0.000 title abstract 3
- 208000012902 Nervous system disease Diseases 0.000 title 1
- 208000025966 Neurological disease Diseases 0.000 title 1
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 abstract 16
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 abstract 16
- 238000000034 method Methods 0.000 abstract 7
- 229920001184 polypeptide Polymers 0.000 abstract 6
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 6
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 abstract 5
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 abstract 5
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 abstract 5
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 abstract 5
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 108060003951 Immunoglobulin Proteins 0.000 abstract 1
- 210000004408 hybridoma Anatomy 0.000 abstract 1
- 102000018358 immunoglobulin Human genes 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Neurosurgery (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
1.- Un método para la inhibición de la unión del Receptor de muerte 6 (DR6) a la proteína precursora amiloide (APP) que suponen la exposición del polipéptido del DR6 y/o del polipéptido de la APP a uno o más antagonistas del DR6 en condiciones en las que se inhibe la unión del DR6 a la APP.2.- El método de la reivindicación 1, donde uno o más de estos antagonistas del DR6 se seleccionen entre un anticuerpo que se une al DR6, un polipéptido del DR6 soluble que comprende los aminoácidos 1-354 de identificador de secuencia n.°: 1, y un anticuerpo que se une a la APP. 3.- El método de la reivindicación 2, donde el polipéptido del DR6 soluble comprende una inmunoadhesina del DR6. 4.- El método de la reivindicación 3, donde el polipéptido del DR6 soluble comprende una secuencia del dominio extracelular del DR6 fusionada con una región Fc de una inmunoglobulina. 5.- El método de la reivindicación 2, donde dicho anticuerpo que se une al DR6 se une a un polipéptido del DR6 que comprende los aminoácidos 1-349 ó 42-349 de la Figura 1 (identificador de secuencia n.°:1). 6.- El método de la reivindicación 2, en el que el anticuerpo que se une al DR6 es un anticuerpo quimérico, humanizado o humano. 7.- El método de la reivindicación 2, en el que el anticuerpo que se une al DR6 inhibe competitivamente la unión del anticuerpo monoclonal 3F4.4.8, 4B6.9.7 ó 1E5.5.7 producido por la línea de células de hibridoma depositada en ATCC con número de depósito PTA-8095, PTA-8094 o PTA-8096, respectivamente.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87152806P | 2006-12-22 | 2006-12-22 | |
| US90084807P | 2007-02-12 | 2007-02-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO6210755A2 true CO6210755A2 (es) | 2010-10-20 |
Family
ID=39535220
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO09074363A CO6210755A2 (es) | 2006-12-22 | 2009-07-16 | Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicos |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20100203044A1 (es) |
| EP (1) | EP2094732A2 (es) |
| JP (1) | JP2010514700A (es) |
| KR (1) | KR20090094854A (es) |
| AR (1) | AR064501A1 (es) |
| AU (1) | AU2007336770A1 (es) |
| BR (1) | BRPI0719459A2 (es) |
| CA (1) | CA2671903A1 (es) |
| CL (1) | CL2007003793A1 (es) |
| CO (1) | CO6210755A2 (es) |
| MX (1) | MX2009006685A (es) |
| NO (1) | NO20092741L (es) |
| NZ (1) | NZ577436A (es) |
| PE (1) | PE20081546A1 (es) |
| RU (1) | RU2009128039A (es) |
| SG (1) | SG177924A1 (es) |
| TW (1) | TW200844113A (es) |
| WO (1) | WO2008080045A2 (es) |
| ZA (1) | ZA201004219B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010062904A2 (en) * | 2008-11-25 | 2010-06-03 | Biogen Idec Ma Inc. | Use of dr6 and p75 antagonists to promote survival of cells of the nervous system |
| TW201034684A (en) * | 2009-02-18 | 2010-10-01 | Genentech Inc | Method for inhibiting neurodegeneration |
| EP2498817A2 (en) * | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
| US9884909B2 (en) | 2010-12-01 | 2018-02-06 | Alderbio Holdings Llc | Anti-NGF compositions and use thereof |
| US9539324B2 (en) | 2010-12-01 | 2017-01-10 | Alderbio Holdings, Llc | Methods of preventing inflammation and treating pain using anti-NGF compositions |
| CN103619879A (zh) | 2010-12-01 | 2014-03-05 | 奥尔德生物控股有限责任公司 | 抗ngf组合物及其用途 |
| US9067988B2 (en) | 2010-12-01 | 2015-06-30 | Alderbio Holdings Llc | Methods of preventing or treating pain using anti-NGF antibodies |
| US9078878B2 (en) | 2010-12-01 | 2015-07-14 | Alderbio Holdings Llc | Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75 |
| US11214610B2 (en) | 2010-12-01 | 2022-01-04 | H. Lundbeck A/S | High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris |
| US20120238465A1 (en) * | 2011-03-17 | 2012-09-20 | Joseph Audie | Drug screening target for alzheimer's disease and method of screening potential drugs |
| CN102708565A (zh) * | 2012-05-07 | 2012-10-03 | 深圳市贝尔信智能系统有限公司 | 一种前景检测的方法、装置和系统 |
| US10634677B2 (en) | 2013-10-14 | 2020-04-28 | Indiana University Research And Technology Corporation | Use of acamprosate to modulate ERK1/2 activation in animal models for FXS and ASD and individuals diagnosed with FXS and ASD |
| JP6555687B2 (ja) | 2013-11-20 | 2019-08-07 | 国立大学法人北海道大学 | 免疫制御剤 |
| US20170174734A1 (en) * | 2014-03-12 | 2017-06-22 | Temple University-Of The Commonwealth System Of Higher Education | DR6 Receptor Mediates the Leukemia Differentiation Activity of Angiocidin: A Potent Anti-Tumor Peptide |
| KR102616160B1 (ko) | 2015-03-16 | 2023-12-22 | 리제너론 파마슈티칼스 인코포레이티드 | 저하된 상위 및 하위 운동 뉴런 기능 및 감각 지각을 나타내는 비-인간 동물 |
| CN112472796A (zh) * | 2015-03-26 | 2021-03-12 | 苏州澳宗生物科技有限公司 | 使用p75ecd和/或p75诊断或治疗神经障碍的方法 |
| US20190127476A1 (en) * | 2016-05-06 | 2019-05-02 | Abbvie Stemcentrx Llc | Novel anti-tnfrsf21 antibodies and methods of use |
| KR102351126B1 (ko) * | 2019-12-03 | 2022-01-13 | 재단법인대구경북과학기술원 | App 및 mdga1 단백질 상호작용 억제제를 포함하는 약학적 조성물 및 이를 이용한 스크리닝 방법 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3702789A1 (de) * | 1987-01-30 | 1988-08-18 | Bayer Ag | Vorlaeuferprotein des apc-polypeptids, dafuer codierende dna und diagnostische verwendung der dna und des proteins |
| DK0417563T3 (da) * | 1989-09-12 | 2000-11-06 | Hoffmann La Roche | TNF-bindende proteiner |
| EP0527823A1 (en) * | 1990-04-24 | 1993-02-24 | The Regents Of The University Of California | Purification, detection and methods of use of protease nexin-2 |
| US5213962A (en) * | 1990-04-24 | 1993-05-25 | The Regents Of The University Of California | Purification, detection and methods of use of protease Nexin-2 |
| US5716805A (en) * | 1991-10-25 | 1998-02-10 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
| US5705401A (en) * | 1991-11-12 | 1998-01-06 | The University Of Melbourne | Method of assaying for alzheimer's disease |
| CA2086165A1 (en) * | 1992-04-09 | 1993-10-10 | Paul P. Tamburini | Diagnostic assay for alzheimer's disease based on the proteolysis of alzheimer's precursor protein |
| US5441870A (en) * | 1992-04-15 | 1995-08-15 | Athena Neurosciences, Inc. | Methods for monitoring cellular processing of β-amyloid precursor protein |
| US6013476A (en) * | 1997-04-02 | 2000-01-11 | Smithkline Beecham Corporation | DNA encoding tumor necrosis related receptor TR7 |
| US6949358B1 (en) * | 1997-06-11 | 2005-09-27 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor TR9 |
| US6358508B1 (en) | 1997-06-11 | 2002-03-19 | Human Genome Sciences, Inc. | Antibodies to human tumor necrosis factor receptor TR9 |
| US7378507B2 (en) * | 1997-09-18 | 2008-05-27 | Genentech, Inc. | PRO217 polypeptides |
| US6194151B1 (en) * | 1997-09-26 | 2001-02-27 | Millenium Pharmaceuticals, Inc. | Molecules of the TNF receptor superfamily and uses therefor |
| FR2778858B1 (fr) * | 1998-05-20 | 2000-06-16 | Oreal | Emulsion e/h/e stable et son utilisation comme composition cosmetique et/ou dermatologique |
| US6916907B1 (en) * | 1998-10-23 | 2005-07-12 | Curagen Corporation | Nucleic acids encoding osteoprotegern-like proteins and methods of using same |
| US6423494B1 (en) * | 1999-03-25 | 2002-07-23 | Millennium Pharmaceuticals, Inc. | DR6 and uses thereof |
| AT5874U1 (de) * | 2000-12-29 | 2003-01-27 | Bioorg Bv | Pharmazeutische zubereitungen enthaltend amlodipinmaleat |
| AU2002255881A1 (en) * | 2001-03-23 | 2002-10-08 | University Of Utah Research Foundation | Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use |
| EP1448601A4 (en) * | 2001-11-02 | 2006-04-26 | Diagenics Internat Corp | METHOD AND COMPOSITIONS OF MONOCLONAL ANTIBODIES SPECIFIC TO BETA-AMYLOIDE PROTEINS |
| US20050208050A1 (en) * | 2001-11-09 | 2005-09-22 | Gerd Multhaup | Compounds for the diagnosis/prevention/treatment of alzheimer's disease |
| US20050069540A1 (en) * | 2001-12-17 | 2005-03-31 | Jinqi Liu | Treating b-cell mediated diseases by modulating dr6 activity |
| EP1444989A1 (en) * | 2003-02-07 | 2004-08-11 | Giorgio Dr. Stassi | Sensitizing cells for apoptosis by selectively blocking cytokines |
| EP1447093A1 (en) | 2003-02-14 | 2004-08-18 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Inhibition of the CD95 ligand/receptor system for the treatment of neurological disorders and injuries |
| AT500483B1 (de) * | 2004-07-13 | 2006-01-15 | Mattner Frank Dr | Set zur vorbeugung oder behandlung der alzheimer'schen erkrankung |
| ES2301280A1 (es) * | 2005-05-16 | 2008-06-16 | Fina Biotech S.L.U. | Metodo para diagnosticar la enfermedad de alzheimer. |
| US20100099609A1 (en) * | 2008-07-28 | 2010-04-22 | Buck Institute For Age Research | eAPP AND DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE |
| EP2498817A2 (en) * | 2009-11-12 | 2012-09-19 | F. Hoffmann-La Roche AG | A method of promoting dendritic spine density |
-
2007
- 2007-12-21 US US12/520,044 patent/US20100203044A1/en not_active Abandoned
- 2007-12-21 KR KR1020097015353A patent/KR20090094854A/ko not_active Application Discontinuation
- 2007-12-21 TW TW096149573A patent/TW200844113A/zh unknown
- 2007-12-21 BR BRPI0719459-5A2A patent/BRPI0719459A2/pt not_active IP Right Cessation
- 2007-12-21 AU AU2007336770A patent/AU2007336770A1/en not_active Abandoned
- 2007-12-21 WO PCT/US2007/088521 patent/WO2008080045A2/en active Application Filing
- 2007-12-21 NZ NZ577436A patent/NZ577436A/en not_active IP Right Cessation
- 2007-12-21 EP EP07869737A patent/EP2094732A2/en not_active Withdrawn
- 2007-12-21 CL CL200703793A patent/CL2007003793A1/es unknown
- 2007-12-21 MX MX2009006685A patent/MX2009006685A/es not_active Application Discontinuation
- 2007-12-21 SG SG2011096492A patent/SG177924A1/en unknown
- 2007-12-21 AR ARP070105866A patent/AR064501A1/es not_active Application Discontinuation
- 2007-12-21 JP JP2009543252A patent/JP2010514700A/ja active Pending
- 2007-12-21 RU RU2009128039/10A patent/RU2009128039A/ru not_active Application Discontinuation
- 2007-12-21 CA CA002671903A patent/CA2671903A1/en not_active Abandoned
-
2008
- 2008-01-02 PE PE2008000033A patent/PE20081546A1/es not_active Application Discontinuation
-
2009
- 2009-07-16 CO CO09074363A patent/CO6210755A2/es not_active Application Discontinuation
- 2009-07-21 NO NO20092741A patent/NO20092741L/no not_active Application Discontinuation
-
2010
- 2010-06-14 ZA ZA2010/04219A patent/ZA201004219B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201004219B (en) | 2013-02-27 |
| AU2007336770A1 (en) | 2008-07-03 |
| KR20090094854A (ko) | 2009-09-08 |
| MX2009006685A (es) | 2009-07-27 |
| SG177924A1 (en) | 2012-02-28 |
| EP2094732A2 (en) | 2009-09-02 |
| CL2007003793A1 (es) | 2008-07-25 |
| RU2009128039A (ru) | 2011-01-27 |
| JP2010514700A (ja) | 2010-05-06 |
| NZ577436A (en) | 2012-05-25 |
| PE20081546A1 (es) | 2008-12-22 |
| WO2008080045A3 (en) | 2008-09-12 |
| BRPI0719459A2 (pt) | 2014-02-04 |
| TW200844113A (en) | 2008-11-16 |
| WO2008080045A2 (en) | 2008-07-03 |
| AR064501A1 (es) | 2009-04-08 |
| US20100203044A1 (en) | 2010-08-12 |
| CA2671903A1 (en) | 2008-07-03 |
| NO20092741L (no) | 2009-09-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO6210755A2 (es) | Antagonistas del dr6 y usos de los mismos en le tratamiento de transtornos neurologicos | |
| JP2020143108A (ja) | 抗ｃｄ３８抗体による併用療法 | |
| DK2567709T3 (en) | Molecules and Methods for Modulating Low-Density Lipoprotein Receptor-Related Protein 6 (LRP6) | |
| JP2021008487A (ja) | 抗ｎｋｇ２ａ抗体を使用した治療計画 | |
| JP5855569B2 (ja) | 破骨細胞特異的抗原の生物学的活性を特異的にブロックする抗体 | |
| KR102294207B1 (ko) | 인간 백혈병 억제 인자 (ｌｉｆ)를 인식하는 항체, 및 원치않는 세포 증식과 관련된 질환 치료에서 항-ｌｉｆ 항체의 용도 | |
| CN108431041A (zh) | 抗siglec-9抗体及其使用方法 | |
| PE20191463A1 (es) | Anticuerpos biespecificos de union especifica pd1 y lag3 | |
| CN108137702A (zh) | 抗siglec-7抗体及其使用方法 | |
| HRP20201733T1 (hr) | Postupci liječenja stanja povezanih s aktivacijom komplementa ovisnim o masp-2 | |
| KR20190028436A (ko) | 과인산화된 타우에 특이적인 항체 및 이의 사용 방법 | |
| CO6180451A2 (es) | Polipeptidos heterodimericos il -17 a/f y usos terapeuticos de los mismos | |
| CN107922480A (zh) | 抗cd33抗体及其使用方法 | |
| AR108377A1 (es) | Proteínas de unión biespecíficas y sus usos | |
| JP2018517431A5 (es) | ||
| RU2011110405A (ru) | Агенты, связывающие рецептор frizzled и их применение | |
| JP2017014219A (ja) | Ｎｏｔｃｈ３アンタゴニストを用いたＮｏｔｃｈ１アンタゴニスト耐性がんの治療 | |
| ES2633297T3 (es) | Anticuerpos monoclonales al factor básico de crecimiento de fibroblastos | |
| RU2011137369A (ru) | Способы лечения воспаления в нейронной ткани с применением моноклонального антитела или его связывающего фрагмента | |
| TW200714711A (en) | Anti-cd-20 monoclonal antibody | |
| RU2017129236A (ru) | Мультивалентные молекулы, содержащие dr5-связывающие домены | |
| AR111830A1 (es) | Anticuerpos monoclonales antagonistas contra cd40 y sus usos | |
| RU2008131052A (ru) | Модуляция костеобразования | |
| MX2012005464A (es) | Un metodo para promover la densidad de espinas dendriticas. | |
| JP2006523087A5 (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |